This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of (Pr)OKEDI® (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia

Newswire.ca - Tue Jun 9, 7:00AM CDT

LAVAL, QC, June 9, 2026 /CNW/ -- Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), resulting in a Letter of Intent (LOI) for PrOKEDI® (Risperidone extended-release injectable suspension) 75mg and 100mg, a long-acting injectable antipsychotic agent for the treatment of schizophrenia in adults.1

Read more at newswire.ca

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).